Skip to main content
Top
Published in: Tumor Biology 5/2010

01-10-2010 | Research Article

Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women

Authors: Emanuela Anastasi, Teresa Granato, Giulia Giovanna Marchei, Valentina Viggiani, Barbara Colaprisca, Sara Comploj, Maria Gabriella Reale, Luigi Frati, Cecilia Midulla

Published in: Tumor Biology | Issue 5/2010

Login to get access

Abstract

The objective of the present study was to investigate in healthy young women the fluctuations in serum concentration of human epididymal secretory protein human epididymis-specific protein 4 (HE4) and CA125 during the phases of the menstrual cycle and the correlation between HE4 and CA125 values and age. Forty women with regular menstrual cycles were included in the study. Pelvic and transvaginal ultrasound were performed in order to exclude ovarian pathologies. Blood samples were collected at follicular (FP), ovulatory (OP), and luteal (LP) phases of the hormonal cycle. The values of HE4 (expressed as picomoles per liter) observed were (mean ± SEM) 39.1 ± 1.1 (FP), 45.3 ± 1.19 (OP), and 42.0 ± 1.3 (LP). The difference between FP and OP was statistically significant (p = 0.0002). By contrast, serum CA125 levels (expressed as units per milliliter) were 14.35 ± 0.66 (FP), 13.15 ± 0.54 (OP), and 13.70 ± 0.54 (LP), respectively. The levels of HE4 observed in serum samples of women below 35 years were 37.5 ± 1.28 in the FP, 46.6 ± 1.4 in the OP, and 42.8 ± 1.49 in the LP. In this group, a statistically significant difference was observed in the FP compared with the OP (p < 0.0001), whereas no statistically significant difference was observed during the different hormonal phases in the group of women over 35. In conclusion, the correct interpretation of laboratory data is essential to define a threshold of normality, and for what concerns HE4 levels, the menstrual cycle phase-dependent variability appears indicated in the interpretation of the results.
Literature
1.
go back to reference Mallett S, Timmer A, Sauerbrei W, Altaman DG. Reporting of prognostic studies of tumor markers: a review of articles in relation to REMARK guidelines. Br J Cancer. 2010;102:173–80.CrossRefPubMed Mallett S, Timmer A, Sauerbrei W, Altaman DG. Reporting of prognostic studies of tumor markers: a review of articles in relation to REMARK guidelines. Br J Cancer. 2010;102:173–80.CrossRefPubMed
2.
go back to reference Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassay for plasma tumor markers. Expert Opin Med Diagn. 2009;3:597–605.CrossRefPubMed Meany DL, Sokoll LJ, Chan DW. Early detection of cancer: immunoassay for plasma tumor markers. Expert Opin Med Diagn. 2009;3:597–605.CrossRefPubMed
3.
go back to reference Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. Pharmacol Ther. 2009;85:134–5.CrossRef Glassman RH, Ratain MJ. Biomarkers in early cancer drug development: limited utility. Pharmacol Ther. 2009;85:134–5.CrossRef
4.
go back to reference Simon R. Clinical trial for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7:33–47.CrossRefPubMed Simon R. Clinical trial for evaluating the medical utility of prognostic and predictive biomarkers in oncology. Per Med. 2010;7:33–47.CrossRefPubMed
5.
go back to reference Bon GS, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, van Kamp GJ, et al. Fluctuations in CA125 and Ca15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod. 1999;14:566–70.CrossRefPubMed Bon GS, Kenemans P, Dekker JJ, Hompes PG, Verstraeten RA, van Kamp GJ, et al. Fluctuations in CA125 and Ca15-3 serum concentrations during spontaneous ovulatory cycles. Hum Reprod. 1999;14:566–70.CrossRefPubMed
6.
go back to reference Kafali H, Artunc H, Herdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 2007;275:175–7.CrossRefPubMed Kafali H, Artunc H, Herdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 2007;275:175–7.CrossRefPubMed
7.
8.
go back to reference Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein is forms. Ontogeny. 2002;21:2768–73. Bingle L, Singleton V, Bingle CD. The putative ovarian tumor marker gene HE4 (WFDC2), is expressed in normal tissues and undergoes complex alternative splicing to yield multiple protein is forms. Ontogeny. 2002;21:2768–73.
9.
go back to reference Claus A, Lila H, Lund wall A. The evolution of a genetic locus encoding small serine proteins inhibitors. Brioche Biophysics Res Common. 2005;333:383–9.CrossRef Claus A, Lila H, Lund wall A. The evolution of a genetic locus encoding small serine proteins inhibitors. Brioche Biophysics Res Common. 2005;333:383–9.CrossRef
10.
go back to reference Claus A, Lila H, Lund wall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acid protein. Brioche J. 2002;368:233–42. Claus A, Lila H, Lund wall A. A locus on human chromosome 20 contains several genes expressing protease inhibitor domains with homology to whey acid protein. Brioche J. 2002;368:233–42.
11.
go back to reference Hellerstrom I, Hellertown KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15–21.CrossRef Hellerstrom I, Hellertown KE. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other. Adv Exp Med Biol. 2008;622:15–21.CrossRef
12.
go back to reference Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010;31:113–9.CrossRef Anastasi E, Marchei GG, Viggiani V, Gennarini G, Frati L, Reale MG. HE4: a new potential early biomarker for the recurrence of ovarian cancer. Tumor Biol. 2010;31:113–9.CrossRef
13.
go back to reference Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA125 levels in differentiating malignant from benign tumors in patients with pelvic mass. Obstet Gynecol. 1988;72:23–7.PubMed Chen DX, Schwartz PE, Li XG, Yang Z. Evaluation of CA125 levels in differentiating malignant from benign tumors in patients with pelvic mass. Obstet Gynecol. 1988;72:23–7.PubMed
14.
go back to reference Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99–105.PubMed Medeiros LR, Rosa DD, da Rosa MI, Bozzetti MC. Accuracy of CA125 in the diagnosis of ovarian tumors: a quantitative systematic review. Eur J Obstet Gynecol Reprod Biol. 2009;142:99–105.PubMed
15.
go back to reference Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 2009;115:1395–403.CrossRefPubMed Tian C, Markman M, Zaino R, Ozols RF, McGuire WP, Muggia FM, et al. CA125 change after chemotherapy in prediction of treatment outcome among advanced mucinous and clear cell epithelial ovarian cancers: a Gynecologic Oncology Group study. Cancer. 2009;115:1395–403.CrossRefPubMed
16.
go back to reference Urban N, McIntosh AM, Karlan B. Ovarian cancer screening. Hematol Oncol Clin North Am. 2003;17:989–1005.CrossRefPubMed Urban N, McIntosh AM, Karlan B. Ovarian cancer screening. Hematol Oncol Clin North Am. 2003;17:989–1005.CrossRefPubMed
17.
go back to reference Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.PubMed Ozols RF. Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol. 2002;20:1161–3.PubMed
18.
go back to reference Boffetta P. Biomarkers in cancer epidemiology an integrative approach. Carcinogenesis. 2009;31:121–6.CrossRefPubMed Boffetta P. Biomarkers in cancer epidemiology an integrative approach. Carcinogenesis. 2009;31:121–6.CrossRefPubMed
19.
go back to reference Riley RD, Saurbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis and beyond. Br J Cancer. 2009;100:1219–29.CrossRefPubMed Riley RD, Saurbrei W, Altman DG. Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis and beyond. Br J Cancer. 2009;100:1219–29.CrossRefPubMed
20.
go back to reference Planchard D, Loriot Y, Goubar A, Commo SJC. Differential expression of biomarkers in men and women. Semin Oncol. 2009;36:553–65.CrossRefPubMed Planchard D, Loriot Y, Goubar A, Commo SJC. Differential expression of biomarkers in men and women. Semin Oncol. 2009;36:553–65.CrossRefPubMed
21.
go back to reference Kafali H, Artuc H, Demir N. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary study. Eur J Obstet Gynecol Reprod Bio. 2004;116:85–8.CrossRef Kafali H, Artuc H, Demir N. Use of CA125 fluctuation during the menstrual cycle as a tool in the clinical diagnosis of endometriosis; a preliminary study. Eur J Obstet Gynecol Reprod Bio. 2004;116:85–8.CrossRef
22.
go back to reference Erbagci AB, Ylmaz N, Kutlar I. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA125 and CA15-3 in healthy women. Dis Markers. 1999;15:259–67.PubMed Erbagci AB, Ylmaz N, Kutlar I. Menstrual cycle dependent variability for serum tumor markers CEA, AFP, CA 19-9, CA125 and CA15-3 in healthy women. Dis Markers. 1999;15:259–67.PubMed
23.
go back to reference Zweers A, de Boever J, Serreyn R, Vandekerckhove D. Correlation between peripheral CA125 and ovarian activity. Fertil Steril. 1990;54:490–4. Zweers A, de Boever J, Serreyn R, Vandekerckhove D. Correlation between peripheral CA125 and ovarian activity. Fertil Steril. 1990;54:490–4.
24.
go back to reference Kafali H, Artunc H, Erdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 2007;275:175–7.CrossRefPubMed Kafali H, Artunc H, Erdem M. Evaluation of factors that may be responsible for cyclic change of CA125 levels during menstrual cycle. Arch Gynecol Obstet. 2007;275:175–7.CrossRefPubMed
25.
go back to reference Creaney J, Robinson BW. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med. 2009;15:366–70.CrossRefPubMed Creaney J, Robinson BW. Serum and pleural fluid biomarkers for mesothelioma. Curr Opin Pulm Med. 2009;15:366–70.CrossRefPubMed
26.
go back to reference Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O. Tumor marker CA125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril. 1993;59:1028–35.PubMed Zeimet AG, Muller-Holzner E, Marth C, Daxenbichler G, Dapunt O. Tumor marker CA125 in tissues of the female reproductive tract and in serum during the normal menstrual cycle. Fertil Steril. 1993;59:1028–35.PubMed
Metadata
Title
Ovarian tumor marker HE4 is differently expressed during the phases of the menstrual cycle in healthy young women
Authors
Emanuela Anastasi
Teresa Granato
Giulia Giovanna Marchei
Valentina Viggiani
Barbara Colaprisca
Sara Comploj
Maria Gabriella Reale
Luigi Frati
Cecilia Midulla
Publication date
01-10-2010
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 5/2010
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-010-0049-1

Other articles of this Issue 5/2010

Tumor Biology 5/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine